You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
TD Cowen
since
auto-detected in 20 stories
27 days ago
Starbucks' strategy shift will drive the stock even higher from where it trades now, according to TD Cowen.
61 days ago
Crypto treasury firms deserve closer attention and these four are buying opportunities, says TD Cowen ⊕⊕
TD Cowen is initiating coverage on four crypto treasury firms – public companies who make it their job to buy and hold crypto to increase shareholder value.
79 days ago
Blue Owl Capital still a buy but will remain choppy through Labor Day, TD Cowen says ⊖
found
TD Cowen reiterated a buy rating on Blue Owl Capital, while lowering its 12-month price target to $14 from $16, according to a report out Monday.
3 months ago
Rivian is a buy ahead of R2 electric vehicle launch, says TD Cowen ○
Rivian Automotive's upcoming R2 model could capitalize on an electric vehicle demand rebound in the U.S., according to TD Cowen.
Mizuho, TD Cowen upgrade Shopify, say AI fears are overdone and LLM strategy builds long-term value ⊕
Mizuho and TD Cowen respectively see Shopify rallying 26% and 34%.
7 months ago
This online banking stock is set to jump as credit outlook improves, says TD Cowen ⊕
Analyst Moshe Orenbuch upgraded the stock to buy from hold.
AMD gets a price target boost from TD Cowen on chipmaker’s partnership with OpenAI ⊕
There may be more upside ahead from AMD's partnership with OpenAI, according to TD Cowen.
8 months ago
Shutdown stocks to watch: These companies get a bulk of their revenues from the government ⊕
A protracted impasse could crimp backlog conversion, slow awards and weigh on cash flow for government services firms, according to TD Cowen.
TD Cowen downgrades Warner Bros. Discovery on concerns a takeover may not happen ○
The latest rally in shares of Warner Bros. Discovery may not hold if a takeover bid from Paramount Skydance doesn't come to fruition, TD Cowen said this week.
10 months ago
Trump's pharmaceutical tariffs could affect some drugmakers more than others ○
found
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.